PureTech Health plc (PTCHF)
| Market Cap | 466.44M |
| Revenue (ttm) | 4.83M |
| Net Income (ttm) | 53.51M |
| Shares Out | n/a |
| EPS (ttm) | 0.21 |
| PE Ratio | 8.72 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 3,961 |
| Open | 1.650 |
| Previous Close | 1.770 |
| Day's Range | 1.650 - 1.770 |
| 52-Week Range | 1.270 - 2.280 |
| Beta | 0.90 |
| RSI | 64.59 |
| Earnings Date | Aug 22, 2025 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]
Financial Performance
Financial StatementsNews
PureTech Health announces CEO transition
PureTech Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.
Why This Biotech Stock Just Doubled In A Single Day
Vor Biopharma Inc. (NASDAQ: VOR) saw its stock climb Thursday following a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies . The developments mark...
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ...
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and Strategic Milestones
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference.
PureTech Health plc 2024 Q4 - Results - Earnings Call Presentation
PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive O...
PureTech Announces Annual Results for Year Ended December 31, 2024
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.
PureTech Health: Notice of Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints Peel Hunt as Joint UK Corporate Broker.
PureTech Health plc Statement Regarding Press Speculation
BOSTON--(BUSINESS WIRE)--Statement regarding press speculation.
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair.
CITIGROUP INC Acquires 10,703,044 Shares in PureTech Health PLC
CITIGROUP INC Acquires 10,703,044 Shares in PureTech Health PLC
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform.
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine.
Zentalis Pharmaceuticals and PureTech Health get Fast Track Designation from FDA for their cancer treatments
FDA grants Fast Track Designation to Zentalis Pharmaceuticals' azenosertib for ovarian cancer and PureTech Health's LYT-200 for leukemia treatment.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML).
PureTech Appoints UBS as UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker.
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Sevasemten in individuals with ...
PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.